The CEO of hearing company GN Hearing's US subsidiary Audigy is now retiring after 17 years in the hot seat. The company, which was acquired by GN Hearing in 2016, has found his replacement within own ranks.
The pharmaceutical industry is fighting against a threat to companies' bottom lines: a global agreement which will harmonize corporation tax.
The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.
In Q2, medtech firm Boston Scientific sold significantly more endoscopy products, which is the core business area of Danish company Ambu. The US giant is upgrading its guidance for the whole year.
Private equity firm Nordic Capital is considering buying healthcare tech firm Inovalon Holdings.
Pharmaceutical company Biontech plans to create a vaccine for malaria based on the same mRNA technology as the firm's vaccine for covid-19, which the German company developed in collaboration with Pfizer.
The New York Times reports that vaccine studies involving children aged 5-11 will be made more comprehensive in the wake of a request from the FDA.
89 percent of the Swedish population above the age of 65 are fully vaccinated, meaning authorities in Sweden are phasing out the use of the AstraZeneca vaccine. In Stockholm, residents now have a choice of vaccines.
Biotech company Allarity Therapeutics has divested a drug candidate to US Lantern Pharma, from which the Danish company in-licensed the drug in 2015. The deal may amount to USD 18m.
From now on, children aged between 12-17 may receive the Moderna vaccine against covid-119, according to the EU CHMP. The Danish Health Authority is taking note.
The US FDA has given biotech firm Saniona's drug candidate Tesomet priority status as an orphan drug for treating hypothalamic obesity. Earlier this year, Tesomet received the same priority status as a treatment for Prader-Willi syndrome.
Japanese firm Kyowa Kirin's Parkinson's disease treatment was given a negative opinion at the council's meeting in July. Two other drugs were recommended for approval.
A new phase III trial in the US will investigate whether extending the patient target group of Lundbeck's drug Vyepti to include younger patients is possible.
The acceleration in sales of Roche's Hemlibra, which competes with Novo Nordisk in an increasingly hot market, has continued. Sales for the first half year totaled more than USD 1.5bn.
"We are now one of the world regions that has vaccinated the most people," says a spokesperson for the EU Commission.
Miss anything?
In less than a year, Danish biotech company Hemab, which builds on technology developed by Novo Nordisk and Genmab, has gone from seed investments to a large capital fund raising round – and now to clinical trials.
Johnson & Johnson's sales figures for Darzalex in the second quarter are so good that Genmab, which developed the drug, may increase its financial expectations for the year, says senior analyst Søren Løntoft Hansen.
Halfway through the accounting year, Biogen predicts a higher revenue than previously expected.
Jordi Llinares Garcia, Head of Research and Innovation at the European Medicines Agency, has died unexpectedly aged just 52.
Prosthetics manufacturer Össur has experienced significant improvements to its growth in Q2 2021, compared to the same period last year which was hugely affected by covid-19.
While Leo Pharma waits for a response to its approval application for eczema treatment Adtralza in the US, it is launching the treatment in the EU, where Head of Europe Monica Shaw can put the experience from launching psoriaris treatment Kyntheum to good use.
Sales of Johnson & Johnson's drug Darzalex totaled USD 1.43bn in Q2, far surpassing analysts' expectations for the drug, which was originally developed by Genmab.
The launch of sclerosis treatment Kesimpta is continuing to go well for Novartis, which has exceeded its financial expectations for the second quarter of this year.
Principal Scientist, Protein Drug Discovery & Development - Y-mAbs Therapeutics A/S 
Senior Clinical Supply Manager - Lundbeck 
Senior QA Specialist - Vaccibody 
(Senior) Regulatory Science Specialist - IWA Consulting 
Bio & Health Data Scientist - ALK-Abelló Associate Director, PV QA - Y-mAbs Therapeutics 
Market Director, Alfanordic 
Business developer within Medical Diagnostics 
Principal Scientist, In Vivo Pharmacology Analytical Coordinator - Symphogen Senior Validation Analyst, Zealand Pharma Senior Clinical Data Manager - Vaccibody 
We are expanding in CleanZone and we are looking for a technical product specialist and technical project manager 
Manager/Associate Director Regulatory Affairs - Ascendis Pharma Medical Writer - Vaccibody Senior Clinical Project Manager - ALK 
KLIFO is looking for a Senior CMC Expert/Senior CMC Project Manager for our Copenhagen office Associate Medical Director, Translational Medicine - Y-mAbs Therapeutics Clinical Development Coordinator - Vaccibody Drug Safety Advisor - ALK Research Laboratory Technician, Immunology/Translational Research - ALK KLIFO is looking for a Senior QA Specialist for our Glostrup office Senior Clinical Development Scientist/Physician - Lundbeck Toxicologist - Lundbeck Quality Manager, Americhem 
